NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced that data from clinical trials of vilazodone, a novel investigational compound for the treatment of major depressive disorder (MDD), were presented at the annual meeting of the American Society of Health System Pharmacists (ASHP). The presentations include results from two Phase I studies. The first study was a Thorough QT Study which evaluated the potential of vilazodone to prolong the QT interval of the electrocardiogram. The second study evaluated the effect of a gastric pH modifier, pantoprazole, on the bioavailability of vilazodone. A New Drug Application (NDA) for vilazodone was accepted for review by the U.S. Food and Drug Administration (FDA) on May 21, 2010 with January 22, 2011 currently assigned for decision-making by the FDA under the Prescription Drug User Fee Act (PDUFA).
